Kornimate/medical-research-clean huggingface dataset:
accuracy of continuous spo2 measurement in adults

Conditions: Healthy

Summary: the purpose of this study is to compare the accuracy of the sotera visi, an investigational device, to standard devices in estimating the level of blood oxygen (spo2) in adult human subjects.

this study is a single-center blinded study that will enroll up to 15 adult subjects, male or female, of any ethnic background. spo2 and pulse rate measurements reported by visi will be compared with simultaneous measurements of blood sao2 and pulse rate made by an fda-cleared co-oximeter and pulse oximeter, respectively. the paired measurements will be made in a well-controlled environment under optimal laboratory conditions.

Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age. * subject is a healthy volunteer capable of undergoing controlled hypoxemia to the level of 70% sao2 (±3%) with no or minimal medical risk. * subject is willing and able to participate in the measurement period for up to two hours. exclusion criteria: * subject has a carboxyhemoglobin level (cohb) ≥3%. * subject has a methb level ≥2%. * subject has a cthb value ≤10g/dl. * subject is in another clinical study that may interfere with the results of this study. * subject is unable or unwilling to have a blood gas and oxygen saturation measurements taken from either wrist/hand. * subject is deemed by the investigator to be medically unsuitable for participation in this study.

Keywords: spo2 oxygen saturation
embryo development using two commercial single-step media

Conditions: Infertility

Summary: this prospective study with sibling oocytes will evaluate the efficiency of two commercial single-step media, namely sage 1-step and continuous single culture medium (cscm), in terms of embryo utilization rates, blastocyst formation rates, embryo quality and pregnancy rates. embryos will be cultured continuously for up to 6 days under identical conditions.


Eligibility criteria:
inclusion criteria: * at least 10 oocytes retrieved exclusion criteria: * frozen oocytes * testicular biopsy * less than 10 oocytes retrieved * older than 40 years

Keywords: single-step media embryo development blastocyst formation embryo utilization
smoking cessation and a teachable moment in patients with acute fractures

Conditions: Tobacco Use Disorder; Bone Fractures

Summary: patients who smoke and suffer from fractures are worse off than those who do not smoke. orthopaedic patients represent a group that can benefit from physician contributions to smoking cessation, and a special opportunity to cue this can begin with the orthopaedic surgeon in the acute setting. however, the best way to appropriately counsel these patients and assess the impact as a teachable moment remains undetermined.

if the patient self-identifies as a smoker, the investigators will consent and randomize to receive the intervention or not. either way, all will receive a baseline attitude survey. the patient will be given a series of questions that target the areas of interest noted in the model. at some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given the teaching intervention (or not), and receive another attitude survey. after discharge, the patients will be expected in orthopaedic follow up clinic. at that time they will receive another attitude survey. if unable to deliver at that time, they will be contacted by phone or sought at their second clinic follow up.

Eligibility criteria:
inclusion criteria: * adults age 18 or over, who are not under the jurisdiction of the department of corrections * individuals receiving care from university of pennsylvania health system clinicians for orthopaedic injuries * individuals who self-identify as smokers exclusion criteria: * under age 18 * under the jurisdiction of the department of corrections * nonsmokers * people not currently receiving fracture care
polyphenol rich aerosol as a support for cancer patients in minimizing side effects after a radiation therapy

Conditions: Oral Mucositis

Summary: the aim of the study is to demonstrate in a clinical condition the effectiveness of a preparation that is a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting cancer patients in minimizing side effects after a radiation therapy cycle.

the study will be conducted on a group of 10 patients with head and neck cancer who have undergone radiation therapy and experience side effects such as discomfort/changes in the oral mucosa.the patients will receive an aerosol for oral use for a period of 1 month. before and after the study, an assessment questionnaire related to the side effects of radiation therapy will be conducted, along with the md anderson dysphagia inventory questionnaire.

Eligibility criteria:
inclusion criteria: * women and men, 18-75 years old * patients with head and neck cancer or other types of cancer after radiotherapy who suffer from oral mucositis * patients with dryness in mouth * signed informed consent. exclusion criteria: * intake of supplements containing plant extracts, polyphenols or anthocyanins * participation in another clinical trial, * women who are pregnant, planning to become pregnant during the study or breastfeeding, * autoimmune disease, severe liver dysfunction, inflammatory bowel disease, tuberculosis, multiple sclerosis, aids, rheumatoid arthritis, organ transplantation. * hypersensitivity/allergy to any of the ingredient

Keywords: radiotherapy head and neck cancer dysphagia oral mucositis
study of zatolmilast (bpn14770) in participants with ppp2r5d neurodevelopmental disorder (jordan's syndrome [js])

Conditions: Jordan's Syndrome; PPP2R5D Neurodevelopmental Disorder

Summary: the primary objective of this study is to assess the safety and tolerability of bpn14770 in participants aged 9 to 45 years with js.


Eligibility criteria:
inclusion criteria: 1. participant is aged 9 to 45 years, inclusive. 2. participant has confirmed/documented history of ppp2r5d neurodevelopmental disorder. 3. current treatment with no more than 3 prescribed psychotropic medications. 4. participant has a parent, legal authorized guardian or consistent caregiver. exclusion criteria: 1. participant has body weight less than 25 kilograms (kg). 2. clinically significant abnormalities, in the investigator's judgment, in safety laboratory tests, vital signs, or electrocardiogram (ecg), as measured during screening. 3. concurrent major psychiatric condition (e.g., major depressive disorder, schizophrenia or bipolar disorder) as diagnosed by the investigator. participants with additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed. 4. participant is planning to commence psychotherapy or cognitive behavior therapy (cbt) during the period of the study or had begun psychotherapy or cbt within 4 weeks prior to screening.

Keywords: jordan's syndrome js ppp2r5d neurodevelopmental disorder zatolmilast bpn14770
allogeneic mesenchymal stem cells in osteoarthritis

Conditions: Osteoarthritis of Knee

Summary: this trial is planed to study if allogeneic mesenchymal stem cells would be safe and beneficial in osteoarthritis of knee joint. this is a double blind study. different doses of stem cells will be used in this study.


Eligibility criteria:
inclusion criteria: 1. males or females in the age 40 - 70 years (both inclusive) 2. radiographic evidence of grade 2 to 3 osteoarthritis based on the kellgren and lawrence radiographic criteria. 3. history of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics. 4. self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs. 5. patients who have been on stable medication which may be nsaids / opioid or opiate analgesics, for the past three months. 6. female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study 7. ability to provide written informed consent. exclusion criteria: 1. prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ecg findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results. 2. history of surgery, or major trauma to the study joint 3. arthroscopy on the study joint in the previous 12 months 4. signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination 5. patients who had received intraarticular steroids or hyaluronan within the last three months. 6. infections in or around the knee. 7. patients awaiting a replacement knee or hip joint 8. patients with other conditions that cause pain 9. patients with deformity of the knee joint. 10. significantly incapacitated or disabled and would be categorized as acr functional class iv (largely or wholly incapacitated), or unable to walk without assistive devices 11. patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis 12. other pathologic lesions on x-rays of knee 13. positive hepatitis b surface antigen, hepatitis c antibody test, anti human immunodeficiency virus (hiv) antibody test, or rpr 14. history of bleeding disorders 15. known hypersensitivity to hyaluronan products or animal sera 16. for women of child-bearing potential: positive pregnancy test or lactating \[females who are planning pregnancy within next one year should be excluded\]

Keywords: osteoarthritis knee stem cells mesenchymal stem cells
pharmacist and family medicine physician collaboration for pre-visit planning and team huddles for ccm patients

Conditions: Chronic Conditions, Multiple

Summary: this is a novel project which incorporates clinic and community pharmacists in three aspects of the patient-centered medical home: pre-visit planning, pre-visit care team huddles, and chronic care management (ccm). patients for the project are enrolled in the neifpc ccm program and have greenwood pharmacy as their primary pharmacy. community and clinic pharmacists will contribute to pre-visit medication reviews and document their drug therapy recommendations in a shared, templated note in the clinic ehr. neifpc pharmacists will attend pre-visit team huddles to relay drug therapy recommendations to the physician. revenue from ccm services will be prorated and shared between greenwood pharmacy and neifpc. the project will last 9 months. primary aims are to describe the pharmacist pre-visit planning service, summarize the billing experience of a community pharmacist providing this service, and to describe the drug therapy interventions made by pharmacists.


Eligibility criteria:
inclusion criteria: * patient enrolled in medicare * patient enrolled in the chronic care management (ccm) program at the northeast iowa family practice center * patient's primary pharmacy is greenwood pharmacy exclusion criteria: * patient not enrolled in medicare * patient not enrolled in ccm program * patient's primary pharmacy is any pharmacy other than greenwood pharmacy
oral formulation of insulin for preterm infants

Conditions: Premature Birth of Newborn

Summary: the study will evaluate the effect of oral formulation of insulin on preterm infants, born between 26-33 weeks of pregnancy, weighing over 750 grams, who meet the inclusion and exclusion criteria established in this protocol.

the study will aim to determine whether an oral formulation of insulin administration enhances gastrointestinal maturation. the gastrointestinal maturation will be evaluated by the ability of premature infants to achieve complete enteral feeds. the insulin concentration administered in the study is physiological and within the insulin concentration range present in human breast milk and colostrum.

Eligibility criteria:
inclusion criteria: 1. pre-term infants 26-33 weeks gestation.
cephalosporin hypersensitivity

Conditions: Drug Hypersensitivity

Summary: background : although the hypersensitivity reactions to cephalosporins have been recently a more focused subject, studies on the cephalosporin as an allergen are significantly less frequent that those regarding penicillins. most of the available data regards cephalosporin sensitization in patients previously allergic to penicillin. like penicillins, cephalosporins represent one of the most prescribed classes of antibiotics. the diagnosis of cephalosporin hypersensitivity is based mainly on clinical history, skin tests (st) and drug provocation tests (dpt). this succession of tests, performed in specialized services, allows to eliminate responsibility for the drug in many cases (80-85%). the drug allergy work-up also allows to identify profiles of allergy to cephalosporins, with different patterns of cross-reactivity. objective: to analyse the characteristics of patients studied in our unit for suspicion of cephalosporin hypersensitivity. methods: this retrospective study will comprise all the patients who attended the allergy service of the uh of montpellier from 1997 till 2018 with a clinical history evocative of cephalosporin drug hypersensitivity reaction (dhr), who underwent a drug allergy work up and who gave their consent to be included in the study . the patients are selected from the drug allergy \& hypersensitivity database (dahd).


Eligibility criteria:
inclusion criteria: - patients with one or more st and dpt tests to cephalosporins exclusion criteria: - patients refusing to take part in the study

Keywords: drug hypersensitivity reaction drug provocation test cephalosporins betalactams risk factor
efficacy and safety of abelmoschus manihot for chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: huangkui capsule is a single medicament of traditional chinese medicine consists of abelmoschus manihot and has been widely used to treat kidney disease. the purpose of this study is to evaluate the safety and efficacy of abelmoschus manihot for treating chronic kidney disease in large scale samples with long time take.

the test has not been completed.

Eligibility criteria:
inclusion criteria: * clinical diagnosed as non-esrd chronic kidney disease (stage i-iv) * blood pressure of ≤140/90mmhg * obtaining the signed informed consent from patients exclusion criteria: * be allergic to huangkui capsule * combined with severe primary diseases of heart, brain, liver and hematopoietic system and so on, or other serious diseases which can affect the patient's life * lactation, pregnancy or plans pregnancy during the study period * participating in another clinical study in the same period

Keywords: abelmoschus manihot chronic kidney disease proteinuria efficacy safety
improving access to renal transplantation for underserved black communities

Conditions: Kidney Transplant; ESRD (End Stage Renal Disease)

Summary: the goal of this clinical trial is to learn whether the african american transplant access program can be successfully replicated at another large kidney transplant program. the main questions it aims to answer are: does the aatap intervention increase the number of black patients who are listed for kidney transplant? does the aatap intervention have an effect on black patient self-efficacy and trust in care team? researchers will compare kidney transplant listing status after 12 months of patients in the aatap intervention to usual care patients to see if the aatap program increases the number of patients listed for transplant.


Eligibility criteria:
inclusion criteria: * self-identify as black or african american; * 18 to 75 years of age * have an egfr \< 20 or end stage renal disease diagnosis; * screen positive for aatap via the screener (for poor health literacy or poor medical adherence or psychosocial concerns); * medically eligible to begin transplant evaluation process determined by transplant team exclusion criteria: * other racial groups * participants who have previously received a transplant; * pregnant women; * participants who screen negative on the screener; * children less than 18 years old

Keywords: heath services research intervention
a validation study of the relationship between aldh2 and aortic dissection

Conditions: Aortic Dissection

Summary: the purpose of this study is to validate the impact of aldh2 glu504lys polymorphism on aortic dissection.


Eligibility criteria:
inclusion criteria: * chinese han people diagnosed with aortic dissection in guangdong provincial people's hospital exclusion criteria: * aortic dissection based on trauma, connective tissue diseases and pregnancy * patients with tumor * patients with no written consensus

Keywords: aortic dissection aldehyde dehydrogenase 2 polymorphism
cholecalciferol intervention to prevent respiratory infections study

Conditions: Respiratory Tract Infection; Vitamin D Deficiency

Summary: this is a feasibility double-blind randomised controlled trial in 32 participants. it evaluates the feasibility of a full trial which will examine the efficacy of weekly supplementation of cholecalciferol (vitamin d3) relative to placebo on the subsequent frequency and severity of objectively-verified symptomatic acute respiratory tract infection, overall and as a proportion of detected colonisations of the upper respiratory tract by 9 of the most common aetiologic viral pathogens.

the hypotheses of the full study are: primary the group treated with vitamin d3 will have a significantly lower frequency of symptomatic respiratory tract infections than controls. secondary 1. among persons with detected viral colonisations of the nasopharynx, treated persons will have a lower frequency of symptomatic respiratory tract infection resultant than controls. 2. treated group will have significantly less severe symptomatic rtis than controls. 3. treated group will have significantly shorter symptomatic rti durations than controls. for the pilot, a cohort of 32 healthy young adults satisfying inclusion criteria will be randomised to cholecalciferol supplement or identical placebo and evaluated daily for the occurrence of rti symptoms and evaluated weekly for the presence of respiratory colonisation by relevant pathogens using nasopharyngeal swab and polymerase chain reaction using selected pathogen-specific primers. this pilot will demonstrate the logistic feasibility of the proposed study design and provide preliminary data which will inform a larger study to be undertaken next year.

Eligibility criteria:
inclusion criteria: * students undertaking study at the ms1 building of university of tasmania medical sciences precinct (17 liverpool st hobart tas) for the full duration between may and september 2012 exclusion criteria: * persons who have used tobacco within the 6 months preceding study entry * persons who have used any vitamin d (cholecalciferol or ergocalciferol) supplements or calcium supplements within the 3 months preceding study entry and/or persons who refuse to not start taking any such supplement during the study * persons using any immunomodulatory medication, diuretic medication, antiepileptic medication, or barbiturates. * persons who presently have been diagnosed with any chronic infectious disease (e.g. hiv, tuberculosis), chronic immune deficiency or autoimmune condition, or respiratory condition (e.g. asthma, chronic obstructive pulmonary disease). * persons who are hypersensitive to vitamin d.

Keywords: vitamin d cholecalciferol respiratory tract infection
analysis of dermal fibroblasts and immune cells during systemic sclerosis

Conditions: Systemic Sclerosis

Summary: the pathophysiology of systemic sclerosis (ssc) is still poorly understood and there are no effective treatments for this disease. ssc is a heterogeneous disease with varying severity. the heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of ssc patients. the immune system, and in particular b lymphocytes, plays a central role in the pathophysiology of ssc. the interactions between b lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated the main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with ssc


Eligibility criteria:
inclusion criteria: * man or woman over 18 years of age * with a systemic sclerosis meeting the acr-eular 2013 criteria having signed an informed consent * being insured exclusion criteria: * syndrome of overlap with another connective tissue disease according to the international diagnostic criteria * immunosuppressive treatment within 12 months * dosage of current corticosteroid therapy ≥10mg/d * protected minors or adults * pregnant or breastfeeding women * deprived of their liberty * persons in emergency situations * persons who have refused or are unable to give informed consent

Keywords: systemic sclerosis fibrosis, fibroblasts. fibroblasts. immune system. b lymphocytes.